These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8172559)

  • 1. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
    Eldering E; Huijbregts CC; Nuijens JH; Hack CE
    Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
    Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
    J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
    Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
    Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of functional human C1 inhibitor in COS cells.
    Eldering E; Nuijens JH; Hack CE
    J Biol Chem; 1988 Aug; 263(24):11776-9. PubMed ID: 2841334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
    Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
    J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of recombinant C1 inhibitor P1 variants.
    Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
    J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of the serpin domain of C1 inhibitor.
    Coutinho M; Aulak KS; Davis AE
    J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
    Sulikowski T; Bauer BA; Patston PA
    Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of C1-inhibitor function by binding to type IV collagen and heparin.
    Patston PA; Schapira M
    Biochem Biophys Res Commun; 1997 Jan; 230(3):597-601. PubMed ID: 9015369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
    de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
    J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
    Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
    Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
    Zahedi R; Wisnieski J; Davis AE
    J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C1 inhibitor mutations which affect intracellular transport and secretion in type I hereditary angioedema.
    Verpy E; Couture-Tosi E; Tosi M
    Behring Inst Mitt; 1993 Dec; (93):120-4. PubMed ID: 8172558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A; Knockaert I; Declerck PJ
    Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers.
    Aulak KS; Davis AE; Donaldson VH; Harrison RA
    Protein Sci; 1993 May; 2(5):727-32. PubMed ID: 8495195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor.
    Bos IG; Lubbers YT; Eldering E; Abrahams JP; Hack CE
    Biochim Biophys Acta; 2004 Jun; 1699(1-2):139-44. PubMed ID: 15158721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.
    Schapira M; Ramus MA; Waeber B; Brunner HR; Jallat S; Carvallo D; Roitsch C; Courtney M
    J Clin Invest; 1987 Aug; 80(2):582-5. PubMed ID: 3497179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats.
    de Smet BJ; de Boer JP; Agterberg J; Rigter G; Bleeker WK; Hack CE
    Blood; 1993 Jan; 81(1):56-61. PubMed ID: 8417802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electron microscope studies of C1s, C1s2, C1r2, C1r2C1s2 and C1-inhibitor.
    Schumaker VN; Phillips ML
    Behring Inst Mitt; 1993 Dec; (93):17-24. PubMed ID: 8172564
    [No Abstract]   [Full Text] [Related]  

  • 20. Serpins and the complement system.
    Beinrohr L; Murray-Rust TA; Dyksterhuis L; Závodszky P; Gál P; Pike RN; Wijeyewickrema LC
    Methods Enzymol; 2011; 499():55-75. PubMed ID: 21683249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.